Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | ($5,458.0K) | ($15.8M) | ($56.7M) | ($117.1M) | ($98.5M) | ($705.8M) | ($959.9M) | ($1,657.7M) | ($1,438.7M) | ($1,789.7M) | ($1,207.7M) |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, BeiGene, Ltd.'s last 12-month Operating Income is ($872.6M), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, BeiGene, Ltd.'s Operating Income growth was (32.5%). The average annual Operating Income growth rates for BeiGene, Ltd. have been (10.4%) over the past three years, 0.5% over the past five years.
Over the last year, BeiGene, Ltd.'s Operating Income growth was (32.5%), which is lower than industry growth of (0.0%). It indicates that BeiGene, Ltd.'s Operating Income growth is Bad.